TROP2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor payload; binds TROP2, internalizes, and releases cytotoxic payload causing DNA damage.
TROP2-directed antibody–drug conjugate that binds TROP2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload to induce DNA damage and tumor cell death.
YES
DIRECT
The ADC binds TROP2 on target cells, is internalized, and releases a topoisomerase I inhibitor payload that induces DNA damage, leading to cell death.
TROP2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor payload; binds TROP2, internalizes, and releases cytotoxic payload causing DNA damage.
TROP2-directed antibody–drug conjugate that binds TROP2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload to induce DNA damage and tumor cell death.
NO
INDIRECT
This ADC binds TROP2 (not Topoisomerase I), is internalized, and releases a payload that inhibits topoisomerase I to induce DNA damage. Cells are killed due to TROP2-directed delivery, not because they express Topoisomerase I.
Autologous, gene-modified chimeric antigen receptor T cells engineered to target both CD19 and BCMA, administered as a single IV infusion to deplete B cells, plasmablasts, and plasma cells, aiming to suppress autoantibody production and B cell–driven inflammation.
Autologous T cells are gene-modified to express chimeric antigen receptors that recognize CD19 and BCMA. After IV infusion, CAR T cells bind CD19+ B cells and BCMA+ plasmablasts/plasma cells, become activated, and lyse these targets via cytotoxic pathways, depleting the B-lineage compartments responsible for autoantibody production and reducing B cell–driven inflammation.
YES
DIRECT
CD19-directed CAR T cells bind CD19+ cells and kill them via T-cell cytotoxic pathways, primarily perforin/granzyme-mediated lysis and apoptosis (and Fas–FasL).
Autologous, gene-modified chimeric antigen receptor T cells engineered to target both CD19 and BCMA, administered as a single IV infusion to deplete B cells, plasmablasts, and plasma cells, aiming to suppress autoantibody production and B cell–driven inflammation.
Autologous T cells are gene-modified to express chimeric antigen receptors that recognize CD19 and BCMA. After IV infusion, CAR T cells bind CD19+ B cells and BCMA+ plasmablasts/plasma cells, become activated, and lyse these targets via cytotoxic pathways, depleting the B-lineage compartments responsible for autoantibody production and reducing B cell–driven inflammation.
YES
DIRECT
BCMA-targeted CAR T cells bind BCMA+ cells, activate, and kill them via perforin/granzyme-mediated cytolysis and apoptotic pathways (e.g., Fas/FasL).
Antibody-drug conjugate targeting TROP2 (also known as iza-bren; izalontamab brengitecan; BMS-986507). Humanized IgG1 mAb linked via a cleavable linker to a camptothecin/topoisomerase-I inhibitor payload, leading to DNA damage and apoptosis; may have Fc-mediated effector and bystander effects.
Humanized IgG1 antibody-drug conjugate that binds TROP2 on tumor cells, is internalized, and releases a cleavable camptothecin/topoisomerase I–inhibitor payload to induce DNA damage and apoptosis; may also elicit Fc-mediated effector functions and bystander killing.
YES
DIRECT
ADC binds TROP2 on tumor cells, is internalized, and releases a cleavable topoisomerase I inhibitor payload causing DNA damage and apoptosis; Fc-mediated effector and bystander killing may also contribute.